AstraZeneca: Imfinzi Plus Chemotherapy Significantly Improves Survival In 1st-line Advanced BTC

(RTTNews) - AstraZeneca PLC (AZN.L, AZN) announced Monday positive high-level results from the TOPAZ-1 Phase III trial that showed Imfinzi (durvalumab) plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer or BTC patients.

(RTTNews) - AstraZeneca PLC (AZN.L, AZN) announced Monday positive high-level results from the TOPAZ-1 Phase III trial that showed Imfinzi (durvalumab) plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer or BTC patients.